Requirement for capital would be the main reason. As always it’s just our capital position that holds us back. Once sorted again we will re rate with FDA trials early next year.
CEO interview on Proactive Investors, page-15
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
0.000(0.00%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 84 | $17.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.55 | 2146 | 3 |
View Market Depth
| Last trade - 15.28pm 23/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |
Day chart unavailable